News

Clearside Biomedical's CLS-AX Trial: A Breakthrough in AMD Treatment

Clearside Biomedical's CLS-AX Trial: A Breakthrough in AMD Treatment

Exciting News from Clearside Biomedical on CLS-AX

Today, the biotech community is buzzing with the latest updates from Clearside Biomedical, Inc. and its innovative approach to treating wet age-related macular degeneration (AMD) through its clinical trials. The company has recently announced promising results from its ODYSSEY Phase 2b trial using CLS-AX (axitinib injectable suspension). This research is significant as it explores a new method of drug delivery to the back of the eye.

Overview of the Clinical Trial

The ODYSSEY trial is a landmark study for Clearside and has achieved its primary and secondary endpoints. This randomized, double-masked study involved 60 participants who had previous treatments for their condition. By using the suprachoroidal delivery method of CLS-AX, the trial focused on stabilizing visual acuity and improving anatomical outcomes over six months, marking a notable advancement in therapy for wet AMD.

Strong Visual Outcomes

One of the most impressive findings from the trial is that patients receiving CLS-AX maintained stable best corrected visual acuity (BCVA) throughout the study. In stark contrast, those given aflibercept, a common treatment, demonstrated less favorable results.

Extended Durability and Reduced Treatment Frequency

Participants treated with CLS-AX showed a significant reduction in their treatment burden. Remarkably, by the six-month mark, 67% of patients did not require additional treatments. This showcases not only the durability of CLS-AX but also its potential to ease the treatment regimens that often overwhelm patients.

The Implications of Positive Safety Profiles

Another notable aspect of the ODYSSEY trial was the positive safety profile of CLS-AX. Participants reported no ocular or treatment-related serious adverse events, which further underscores the reliability of this new therapeutic approach. As the Chief Executive Officer, George Lasezkay, expressed, the results serve as a beacon of hope for future clinical advancement, potentially leading to phase 3 development of CLS-AX.

Clinical Possibilities and Future Directions

Given the positive feedback from the trial, Clearside Biomedical is optimistic about the future of CLS-AX. The innovative method of drug delivery via the suprachoroidal space presents a host of benefits over traditional injection methods, including fewer injections and extensive patient comfort. This capability could redefine treatment protocols for wet AMD, promising both effectiveness and convenience.

Expert Commentary on CLS-AX Potential

According to Victor Chong, M.D., the Chief Medical Officer of Clearside, the results confirm the ability to administer multiple doses from 12 to 36 weeks, highlighting a significant advantage over current treatment options. With CLS-AX’s unique delivery system, patients might experience a notable improvement in their quality of life.

The Broader Impact of Age-Related Macular Degeneration

The issue of age-related macular degeneration is considerable. A large number of adults suffer from this progressive condition, which leads to a gradual loss of central vision and significantly impairs everyday activities. The burden of frequent injections and the associated healthcare costs combined create challenges for patients and the healthcare system.

Looking Ahead with CLS-AX

As Clearside Biomedical moves forward with its ambitions for CLS-AX in the treatment of neovascular AMD, expectations are high for the ongoing research in this critical disease area. The potential advantages of CLS-AX treatment—specifically its long-acting nature and reduced injection burden—underline the importance of this research.

Frequently Asked Questions

What is the ODYSSEY trial?

The ODYSSEY trial is a Phase 2b clinical study designed to evaluate the efficacy and safety of CLS-AX for treating wet AMD over 36 weeks.

What were the trial results for CLS-AX?

CLS-AX maintained stable visual acuity and reduced the need for additional treatments, demonstrating a significant improvement in patient outcomes compared to traditional therapies.

How does CLS-AX work?

CLS-AX is an injectable suspension delivered via the suprachoroidal space directly to the affected areas behind the retina, allowing for prolonged effect and reduced treatment burden.

What are the safety results of CLS-AX?

The trial reported a positive safety profile with no ocular or treatment-related serious adverse events, indicating a strong tolerance among participants.

What does this mean for future AMD treatments?

The success of CLS-AX may lead to a new standard of care for wet AMD, focusing on long-lasting treatments that require fewer injections, greatly improving adherence among patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Dyne Therapeutics Faces Legal Inquiry Amid FDA Approval Delays

Updated Category News Views 189

Understanding the Investigation Surrounding Dyne Therapeutics Recently, Pomerantz LLP, a recognized law firm, initiated an investigation on behalf of investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). The focus of this inquiry is on whether Dyne and its executives have participated in unlawful business practices, including securities fraud. These claims arise amidst...

Continue Reading
ThermAI Secures Major Investment from Tech Visionary Daniel Keller

Updated Category News Views 334

ThermAI's Innovative Breakthrough in Heat Recovery Technology ThermAI, a groundbreaking decentralised compute and heat-recovery protocol, has recently secured a strategic investment from Daniel Keller, a prominent figure in the tech industry known for co-founding Flux and playing a pivotal role in architecting Zelcore. This partnership is set to expedite ThermAI's...

Continue Reading
CAPTRUST Expands Reach with Carolinas Investment Consulting

Updated Category News Views 119

CAPTRUST Welcomes Carolinas Investment Consulting CAPTRUST Financial Advisors, known for their commitment to excellent service in the financial advisory realm, is embracing a new chapter with the addition of Carolinas Investment Consulting (CIC). This collaboration aims to deliver enhanced investment consulting and financial planning services to an even broader clientele....

Continue Reading
Essential Vehicle Preparations for College Students

Updated Category News Views 141

Get Your Car Ready for College Mercury Insurance Provides a Checklist to Make Sure You're Prepared As the academic year approaches, it's that time when students gear up to head back to campus. Whether you're a parent assisting your child or a student planning to drive yourself, it's crucial to ensure that your vehicle is ready for the journey ahead. Understanding this...

Continue Reading
Cineverse Unveils cineSearch: Revolutionizing Streaming Search

Updated Category News Views 406

Cineverse Introduces cineSearch for Enhanced Content Discovery AI-Powered cineSearch Unlocks Personalized Content Recommendations Across Leading Streaming Platforms Cineverse Corp. (NASDAQ: CNVS), an innovative streaming technology and entertainment company, is excited to announce the public preview of cineSearch, its groundbreaking AI-driven content discovery tool....

Continue Reading